Antimicrobial activity of some sulfonamide derivatives on clinical isolates of Staphylococus aureus

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p> <jats:italic>Staphylococcus aureus</jats:italic> is a non-motile, gram positive, non-sporforming, facultative anaerobic microorganism. It is one of the important bacteria as a potential pathogen specifically for nosocomial infections. The sulfonamide derivative medicines are preferred to cure infection caused by <jats:italic>S. aureus</jats:italic> due to methicillin resistance.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Antimicrobial activity of four sulfonamide derivatives have been investigated against 50 clinical isolates of <jats:italic>S. aureus</jats:italic> and tested by using MIC and disc diffusion methods. 50 clinical isolate which collected from specimens of patients who are given medical treatment in Ondokuz Mayis University Medical School Hospital. A control strain of <jats:italic>S. aureus</jats:italic> ATCC 29213 was also tested.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>The strongest inhibition was observed in the cases of <jats:bold>I</jats:bold> [<jats:italic>N</jats:italic>-(2-hydroxy-4-nitro-phenyl)-4-methyl-benzensulfonamid], and <jats:bold>II</jats:bold> [<jats:italic>N</jats:italic>-(2-hydroxy-5-nitro-phenyl)-4-methyl-benzensulfonamid] against <jats:italic>S. aureus</jats:italic>. Compound <jats:bold>I</jats:bold> [<jats:italic>N</jats:italic>-(2-hydroxy-4-nitro-phenyl)-4-methyl-benzensulfonamid] showed higher effect on 21 <jats:italic>S. aureus</jats:italic> MRSAisolates than oxacillin antibiotic. Introducing an electron withdrawing on the ring increased the antimicrobial activity remarkably.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>This study may help to suggest an alternative possible leading compound for development of new antimicrobial agents against MRSA and MSSA resistant <jats:italic>S. aureus</jats:italic>. It was also shown here that that clinical isolates of 50 <jats:italic>S. aureus</jats:italic> have various resistance patterns against to four sulfonamide derivatives. It may also be emphasized here that in vitro antimicrobial susceptibility testing results for <jats:italic>S. aureus</jats:italic> need standardization with further studies and it should also have a correlation with in vivo therapeutic response experiments.</jats:p> </jats:sec>